Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$10.18
-$0.43(-1.58%)
At close: 4:00 PM EST
$10.18
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$4.68 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)886.87K
Market Cap
$162.42M
Enterprise Value$29.17
Total Cash (Recent Filing)$258.38M
Total Debt (Recent Filing)$673.00K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Aug 19, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding31,354,395
10 Day Avg. Volume1,186,112
30 Day Avg. Volume886,872
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.20Price Target Upside216.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.49
Revenue Forecast (FY)$18.95M
Bulls Say, Bears Say
Bulls Say
High Product Gross MarginsVery high product gross margins and management’s ~90% gross‑margin target indicate strong scalable unit economics. When fixed commercial and SG&A costs are absorbed, the product can convert incremental revenue to operating profit rapidly, improving long‑term margin sustainability and cash generation potential.
Rapid Prescriber AdoptionA large and growing prescriber base with meaningful repeat prescribing signals durable distribution penetration. Broad physician adoption reduces per‑unit acquisition costs over time, supports predictable refill cohorts, and increases the likelihood of sustained revenue growth as the company scales its commercial footprint.
Strong Cash Position & Low LeverageA sizable cash balance combined with negligible debt materially lowers near‑term refinancing risk and gives management runway to fund commercialization, field expansion and operational improvements. This capitalization provides strategic optionality and reduces immediate pressure to raise dilutive capital.
Bears Say
Sustained Negative Cash FlowPersistently negative operating and free cash flow means the business remains funding operations via external capital. Continued high cash consumption increases dilution risk, constrains discretionary investments, and extends the timeline to self‑funded growth unless revenue scale or cash conversion meaningfully improves.
Elevated SG&A And Operating LossesLarge, front‑loaded commercial spending and sizable operating losses create a high fixed‑cost structure that requires substantial and sustained revenue growth to reach breakeven. If adoption or refill trends soften, high SG&A will prolong operating losses and pressure margin recovery.
Uncertain Refill Dynamics & AdoptionDelayed cohort refill data and slower new‑patient starts create uncertainty about repeat usage and long‑term patient lifetime value. Physician behavioral barriers and ongoing competitor sampling raise execution risk, making durable revenue predictability and payor/provider acceptance uncertain through the next several quarters.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $4.68 and its highest was $50.40 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $162.42M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 31 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.048 by -$0.272.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -1.05.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 31,354,395 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.048. Following the earnings report the stock price went down -20.821%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (216.31% Upside)
$32.20 (216.31% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.01%
12-Months-Change
Fundamentals
Return on Equity
-46.82%
Trailing 12-Months
Asset Growth
35.42%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
LENZ Stock 12 Month Forecast
Average Price Target
$32.20
▲(216.31% Upside)
Technical Analysis
Ownership Overview
15.24% Insiders
15.87% Mutual Funds
0.07% Other Institutional Investors
59.98% Public Companies and
Individual Investors